Intervention
Stereotactic Radiation
ClinicalTrials.gov intervention label
Clinical trials
5 shownSacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain MetastasesNCT06238921 · 2024-12-19
RECRUITINGStereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain MetastasesNCT04899908 · 2021-09-15
RECRUITINGStereotactic Radiotherapy (SBRT) of Lung MetastasisNCT01803542 · 2006-03-01
RECRUITINGStereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain MetastasesNCT03391362 · 2018-02-23
ACTIVE_NOT_RECRUITINGPhase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CANCT02685332 · 2016-03-31
ACTIVE_NOT_RECRUITINGCommon conditions
Brain Metastases2Breast Cancer2AGuIX1Brain Cancer1Brain Tumor1Colorectal Cancer1Cystic1Early Stage Breast Cancer1Gastrointestinal Cancer1HER2-positive Breast Cancer1Lung Cancer1Melanoma1Metastasis From Other Cancers1Nanoparticle1Non-small Cell Lung Cancer1Small Cell Lung Cancer1SRS1SRT1Stereotactic Radiation1Triple Negative Breast Cancer1Whole Brain Radiation1
Leading sponsors
Trial status mix
RECRUITING3
ACTIVE_NOT_RECRUITING2
Phase mix
PHASE23
PHASE12
NA1
How to interpret this record
CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.